A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults

Clinical Pharmacokinetics

Volumn 52, Issue 7, 2013, Pages 555-565

  Ince, Ibrahim ^a,b   De Wildt, Saskia N ^a   Wang, Chengueng ^a,b   Peeters, Mariska Y M ^c   Burggraaf, Jacobus ^d   Jacqz Aigrain, Evelyne ^e   Van Den Anker, John N ^f   Tibboel, Dick ^a   Danhof, Meindert ^b   Knibbe, Catherijne A J ^a,b,c  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM;

ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CRANIOFACIAL SURGERY; DRUG CLEARANCE; GESTATIONAL AGE; HUMAN; INTENSIVE CARE; LIFESPAN; MATURATION; NEWBORN; PREMATURITY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANESTHETICS, INTRAVENOUS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; HUMANS; HYPNOTICS AND SEDATIVES; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; MIDAZOLAM; MODELS, BIOLOGICAL; YOUNG ADULT;

EID: 84879670026     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0050-0     Document Type: Article

References (49)

1. Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene. 2000;260(1-2):13-23.
2. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1-17.
3. Peeters MY, Prins SA, Knibbe CA, et al. Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology. 2006;105(6):1135-46.
4. Reed MD, Rodarte A, Blumer JL, et al. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol. 2001;41(12):1359-69.
5. Rey E, Delaunay L, Pons G, et al. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. Eur J Clin Pharmacol. 1991;41(4):355-7.
6. de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clin Pharmacol Ther. 2001;70(6):525-31.
7. Jacqz-Aigrain E, Wood C, Robieux I. Pharmacokinetics of midazolam in critically ill neonates. Eur J Clin Pharmacol. 1990;39(2):191-2.
8. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics. 1994;4(4):171-84.
9. de Wildt SN, Ito S, Koren G. Challenges for drug studies in children: CYP3A phenotyping as example. Drug Discov Today. 2009;14(1-2):6-15.
10. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270(1):414-23.
11. Ince I, de Wildt SN, Peeters MY, et al. Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. Ther Drug Monit. 2012;34(4):381-9.
12. Burtin P, Jacqz-Aigrain E, Girard P, et al. Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther. 1994;56(6 Pt 1):615-25.
13. Jacqz-Aigrain E, Daoud P, Burtin P, et al. Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. Eur J Clin Pharmacol. 1992;42(3):329-32.
14. Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997;247(2):625-34.
15. Stevens JC, Hines RN, Gu C, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther. 2003;307(2):573-82.
16. de Wildt SN, de Hoog M, Vinks AA, et al. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med. 2003;31(7):1952-8.
17. de Wildt SN, Riva L, van den Anker JN, Murray DJ. Does age alter the pharmacokinetics of midazolam and l-OH-midazolam in paediatric patients? [abstract no. PI-60]. Clin Pharmacol Ther. 2000;67:104.
18. Jacqz-Aigrain E, Daoud P, Burtin P, et al. Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies. Lancet. 1994;344(8923):646-50.
19. van Gerven JM, Roncari G, Schoemaker RC, et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol. 1997;44(5):487-93.
20. Boeckmann AJ, Beal SL, Sheiner LB. NONMEM User's Guide. California: Division of Clinical Pharmacology, University of California at San Francisco; 1998.
21. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17-20.
22. Montgomery DC, Peck EA, Vining GG. Introduction to linear regression analysis. New York: Wiley; 1982.
23. Wang C, Peeters MY, Allegaert K, et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res. 2012.
24. Bartelink IH, Boelens JJ, Bredius RG, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012;51(5):331-45.
25. Krekels EH, van Hasselt JG, Tibboel D, et al. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res. 2011;28(4):797-811.
26. Ette EI, Williams PJ, Kim YH, et al. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003;43(6):610-23.
27. Brendel K, Comets E, Laffont C, et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23(9):2036-49.
28. Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate non-linear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90(2):154-66.
29. Kumar P, Denson SE, Mancuso TJ. Premedication for nonemergency endotracheal intubation in the neonate. Pediatrics. 2010;125(3):608-15.
30. VanLooy JW, Schumacher RE, Bhatt-Mehta V. Efficacy of a premedication algorithm for nonemergent intubation in a neonatal intensive care unit. Ann Pharmacother. 2008;42(7):947-55.
31. Anand KJ, Barton BA, McIntosh N, et al. Analgesia and sedation in preterm neonates who require ventilatory support: results from the NOPAIN trial. Neonatal outcome and prolonged analgesia in neonates. Arch Pediatr Adolesc Med. 1999;153(4):331-8.
32. de Wildt SN, de Hoog M, Vinks AA, et al. Pharmacodynamics of midazolam in pediatric intensive care patients. Ther Drug Monit. 2005;27(1):98-102.
33. Gorski JC, Hall SD, Jones DR, et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994;47(9):1643-53.
34. Hakkola J, Pasanen M, Purkunen R, et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem Pharmacol. 1994;48(1):59-64.
35. Blake MJ, Gaedigk A, Pearce RE, et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther. 2007;81(4):510-6.
36. Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol. 2007;21(4):169-75.
37. Johnson TN, Tucker GT, Rostami-Hodjegan A. Development of CYP2D6 and CYP3A4 in the first year of life. Clin Pharmacol Ther. 2008;83(5):670-1.
38. Leeder JS, Gaedigk R, Marcucci KA, et al. Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005;314(2):626-35.
39. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931-56.
40. Anderson BJ, Larsson P. A maturation model for midazolam clearance. Paediatr Anaesth. 2011;21(3):302-8.
41. Khandelwal AHAC, Karlsson MO. Influence of correlated covariates on predictive performance for different models. [abstract no. 2220]. PAGE 20; 7-11 Jun 2011; Athens.
42. Barrett JS, Della Casa Alberighi O, Laer S, et al. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther. 2012;92(1):40-9.
43. Walsky RL, Obach RS, Hyland R, et al. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos. 2012;40(9):1686-97.
44. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35(9):1687-93.
45. Kearney RA, Rosales JK, Howes WJ. Craniosynostosis: an assessment of blood loss and transfusion practices. Can J Anaesth. 1989;36(4):473-7.
46. Ince I, de Wildt SN, Tibboel D, et al. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today. 2009;14(5-6):316-20.
47. Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet. 2008;47(4):231-43.
48. Krekels EH, DeJongh J, van Lingen RA, et al. Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet. 2011;50(1):51-63.
49. Kearns GL, Robinson PK, Wilson JT, et al. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther. 2003;74(4):312-25.